TY - JOUR
T1 - Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma
T2 - Contribution to the Development of Response Criteria for Relapsed or Progressive Disease
AU - Kluge, Regine
AU - Wittig, Tim
AU - Georgi, Thomas W
AU - Kurch, Lars
AU - Sabri, Osama
AU - Wallace, W Hamish
AU - Klekawka, Tomasz
AU - Fernández-Teijeiro, Ana
AU - Ceppi, Francesco
AU - Karlén, Jonas
AU - Pears, Jane
AU - Cepelová, Michaela
AU - Fosså, Alexander
AU - Beishuizen, Auke
AU - Hjalgrim, Lisa Lyngsie
AU - Körholz, Dieter
AU - Mauz-Körholz, Christine
AU - Hasenclever, Dirk
N1 - © 2021 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2021/3
Y1 - 2021/3
N2 - In first-line treatment of Hodgkin lymphoma (HL), Deauville scores 1-3 define complete metabolic remission. Interim 18F-FDG PET is also used for relapse-treatment adaptation; however, PET response criteria are not validated for relapse treatment. Methods: We performed a pairwise comparative analysis of early response to first- and second-line treatments in 127 patients with classic HL who experienced relapse. The patients participated in the prospective, multicenter EuroNet-PHL-C1 study. Residual uptake was measured retrospectively using the qPET method, a validated semiautomatic quantitative extension of the Deauville score. Empiric cumulative distribution functions of the qPET values were used to systematically analyze the response to first- and second-line treatments. Results: Individual patients responded variably to first- and second-line treatments. However, the empiric cumulative distribution functions of the qPET values from all patients were nearly superimposable. Conclusion: The findings support that first- and second-line treatments in HL do not require different response criteria.
AB - In first-line treatment of Hodgkin lymphoma (HL), Deauville scores 1-3 define complete metabolic remission. Interim 18F-FDG PET is also used for relapse-treatment adaptation; however, PET response criteria are not validated for relapse treatment. Methods: We performed a pairwise comparative analysis of early response to first- and second-line treatments in 127 patients with classic HL who experienced relapse. The patients participated in the prospective, multicenter EuroNet-PHL-C1 study. Residual uptake was measured retrospectively using the qPET method, a validated semiautomatic quantitative extension of the Deauville score. Empiric cumulative distribution functions of the qPET values were used to systematically analyze the response to first- and second-line treatments. Results: Individual patients responded variably to first- and second-line treatments. However, the empiric cumulative distribution functions of the qPET values from all patients were nearly superimposable. Conclusion: The findings support that first- and second-line treatments in HL do not require different response criteria.
KW - Adolescent
KW - Child
KW - Disease Progression
KW - Female
KW - Hodgkin Disease/diagnostic imaging
KW - Humans
KW - Male
KW - Positron-Emission Tomography
KW - Recurrence
KW - Treatment Outcome
UR - http://www.scopus.com/inward/record.url?scp=85102217914&partnerID=8YFLogxK
U2 - 10.2967/jnumed.120.247924
DO - 10.2967/jnumed.120.247924
M3 - Journal article
C2 - 32764122
SN - 0161-5505
VL - 62
SP - 338
EP - 341
JO - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
JF - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
IS - 3
ER -